Testagen
Testagen is a complex peptide bioregulator preparation targeting testicular tissue, developed at the St. Petersburg Institute of Bioregulation and Gerontology for research in male reproductive aging, testosterone regulation, and spermatogenesis. It is part of the Cytomed line of tissue-specific peptide bioregulators.
Testagen is a complex peptide preparation derived from young animal testicular tissue, designed to selectively target cells of the male reproductive system. Developed under the direction of Vladimir Khavinson at the St.
Overview
Testagen was developed as part of a systematic program to create tissue-specific peptide bioregulators for each major organ and gland in the body. The preparation is obtained through acid extraction and purification of testicular tissue from young animals, yielding a mixture of low-molecular-weight peptides hypothesized to carry tissue-specific regulatory signals.
The primary research interest in testagen relates to age-related decline in male reproductive function, including reduced testosterone production by Leydig cells and diminished spermatogenesis. The hypothalamic-pituitary-gonadal axis undergoes progressive changes with aging, and testagen is proposed to act at the testicular level to support cellular function and gene expression in aging testes.
Mechanism of Action
Like other Khavinson bioregulators, testagen is proposed to function through selective interaction with DNA in target tissue cells, modulating gene expression patterns toward a more youthful phenotype. In testicular tissue, this is hypothesized to involve:
- Regulation of steroidogenic gene expression in Leydig cells, including enzymes in the testosterone biosynthesis pathway such as StAR protein, CYP11A1, and 3beta-HSD
- Modulation of Sertoli cell function to support spermatogenesis
- Normalization of growth factor and cytokine expression in the testicular microenvironment
The broader theoretical framework, described by Khavinson (2005), proposes that short peptides interact with specific DNA sequences to influence chromatin condensation states, thereby reactivating genes that become silenced during aging.
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Male Reproductive Aging
Research on testicular peptide preparations has examined their effects on age-related decline in testosterone production. In animal models of reproductive aging, administration of testis-derived peptide complexes was associated with partial restoration of testosterone levels and improved histological markers in testicular tissue. Khavinson's group reported that peptide bioregulators could modulate the functional state of the hypothalamic-pituitary-gonadal axis through peripheral tissue effects (Khavinson, 2002, Neuro Endocrinol Lett).
Spermatogenesis
Preclinical studies examined the effects of testicular peptide preparations on spermatogenesis in aging animals. Results suggested improvements in sperm count and motility parameters, with histological evidence of increased spermatogenic activity in seminiferous tubules. These findings were consistent with the broader observation that tissue-specific peptide bioregulators can partially reverse age-related functional decline in their target organs.
Peptide Bioregulation and Hormonal Axes
The relationship between peptide bioregulators and endocrine function has been explored in several studies from the St. Petersburg Institute. Khavinson's group demonstrated that combinations of tissue-specific peptide preparations could produce coordinated effects across endocrine axes. For example, epithalon (targeting the pineal gland) combined with testicular peptides showed additive effects on reproductive parameters in aging animals (Anisimov et al., 2003).
Safety Profile
Testagen has been available as a dietary supplement in Russia for over a decade with no significant adverse effects reported in available literature. As a preparation of naturally derived short peptides administered orally, systemic bioavailability and potency are expected to be modest. No formal clinical safety trials meeting international regulatory standards have been published. Men with hormone-sensitive conditions (prostate cancer, testosterone-dependent disorders) should exercise caution and consult medical professionals before use.
Pharmacokinetic Profile
- Half-life
- Not established
- Tmax
- 15 min
Quick Start
- Typical Dose
- 10-20mg daily during cycle
- Frequency
- Daily for 10-20 days, then break
- Route
- Oral (capsules)
- Cycle Length
- 10-20 day cycles (typical bioregulator protocol)
- Storage
- Capsules: room temperature. Reconstituted: 2-8°C
Molecular Structure
- Formula
- Not applicable (multi-peptide preparation)
- Weight
- 419 Da
- Length
- 4 amino acids
- CAS
- Not available
Research Indications
Male Hormone Support
Promotes testosterone biosynthesis through Leydig cell stimulation.
Restores normal communication within hypothalamic-pituitary-gonadal axis.
Addresses declining testosterone through cellular metabolism improvement.
Male Reproductive Health
Supports spermatogenesis and reproductive balance.
Normalizes testicular function by reducing peptide deficiency.
May enhance male sexual function through testosterone support.
Prostate Support
Research shows reduction in inflammation markers in prostate tissue.
Research Protocols
oral
Available in capsule form for oral administration. Short peptides can be absorbed orally and reach target tissues. Typical protocol involves 10-20 day cycles.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Standard protocol | 10-20 mg | Daily for 10-20 days | —(Route: Oral capsules) |
subcutaneous Injection
Testicular bioregulator. Very low doses — use 30 or 50-unit insulin syringe for accuracy.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Loading phase | 100 mcg | Once daily | Weeks 1-2 |
| Escalation 1 | 150 mcg | Once daily | Weeks 3-4 |
| Escalation 2 | 200 mcg | Once daily | Weeks 5-8 |
| Full dose | 250-300 mcg | Once daily | Weeks 9-12(Cycle 8-12 weeks, extendable to 16) |
Reconstitution Guide (20mg vial + 3mL BAC water)
- Wipe vial tops with alcohol swab
- Draw 3.0 mL bacteriostatic water into syringe
- Inject slowly down the inside wall of the peptide vial
- Gently swirl to dissolve — never shake
- Resulting concentration: 6.67 mg/mL
- For 100 mcg dose: draw 1.5 units (0.015 mL) — use 30-unit syringe
- For 200 mcg dose: draw 3 units (0.03 mL)
- For 300 mcg dose: draw 4.5 units (0.045 mL)
- Store reconstituted vial refrigerated at 2-8°C
Interactions
Peptide Interactions
For example, epithalon (targeting the pineal gland) combined with testicular peptides showed additive effects on reproductive parameters in aging animals ([Anisimov et al.
What to Expect
What to Expect
Gene expression modulation and cellular metabolism changes begin
Effects persist due to epigenetic changes
Testosterone and reproductive function improvements
Cumulative benefits with periodic cycles
Safety Profile
Common Side Effects
- Generally well-tolerated
- Minimal side effects reported
Contraindications
- Hormone-sensitive cancers (consult oncologist)
- Known hypersensitivity
- Female use not established
Discontinue If
- Allergic reactions
- Signs of hormone imbalance
Quality Indicators
What to look for
- White powder or capsules
- Clear solution if reconstituted
- Proper packaging and labeling
Caution
- Unknown source or purity
Red flags
- Discoloration
- Unusual odor
- Damaged packaging
Frequently Asked Questions
References (9)
- [9]Khavinson VKh et al Short peptides: regulation of gene activity and application in gerontology. Adv Gerontol (2021)
- [1]Testagen Bioregulator Research on Testosterone and Leydig Cells (2018)
- [2]Short Peptides and HPG Axis Function (2016)
- [3]Epigenetic Effects of Short Peptides (2014)
- [4]Khavinson Peptide Bioregulators (2020)
- [2]Khavinson VKh (2002). Peptides and ageing. Neuro Endocrinol Lett (2002)
- [3][Anisimov VN et al. (2003). Effect of Epithalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology (2003)
- [4][Ashapkin V et al. (2020). Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Mol Biol Rep (2020)
- [1][Khavinson VKh & Malinin VV (2005). Gerontological aspects of genome peptide regulation. Karger (2005)
Tesamorelin
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue approved under the brand name Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Thymalin
Thymalin is a thymus-derived dipeptide complex (Glu-Trp) developed in Russia for immune restoration, particularly in aging populations. It modulates T-cell differentiation, cytokine balance, and has been studied for its interactions with the pineal gland via the pineal-thymus axis.